ACL InjuryBFRNCT03794570
BFR Therapy After ACL Reconstruction
A study testing Blood flow restriction therapy - with Delfi Personalized Tourniquet System in people with ACL Injury and Quadriceps Muscle Atrophy, run by Steadman Philippon Research Institute at 1 site in United States.
Trial summary
This study is a prospective, double-blinded, randomized control trial examining the effect of blood flow restriction (BFR) therapy on reducing post-operative quadriceps atrophy in patients undergoing anterior cruciate ligament reconstruction (ACLR). Read more about this study
- Who is it for?
- Ages 14 to 70 years
- Conditions the study is for
- ACL Injury, Quadriceps Muscle Atrophy
- What is being tested?
- Blood flow restriction therapy - with Delfi Personalized Tourniquet System
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 0 participants
- Where
- 1 siteUnited States
- Study dates
- 18 Dec 2018to 1 Jun 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 14 to 70 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Age 14-70
- Undergoing ACL reconstruction with patellar tendon autograft
- Full weightbearing after surgery
- Surgery performed within 14 days of ACL injury
- No nerve catheter in place
Who cannot join
- Meniscal root tears
- radial meniscal tears
- multi-ligament knee injury
- revision ACL reconstruction
- concomitant osteotomies
- concomitant cartilage resurfacing procedures
Show all 15Show fewer
- fracture preventing full-weightbearing of operated extremity
- previous history of deep vein thrombosis (DVT)
- new nerve injury/findings affecting operative extremity
- active femoral nerve catheter
- nerve block lasting longer than day of surgery
- patients unable to tolerate BFR treatment
- untolerable post-operative pain due to absence of nerve catheter
- proximal thigh girth greater than 34cm
- time to surgery greater than 14 days
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Blood Flow Restriction Therapy to Prevent Muscle Atrophy Following Anterior Cruciate Ligament Reconstruction
This study is a prospective, double-blinded, randomized control trial examining the effect of blood flow restriction (BFR) therapy on reducing post-operative quadriceps atrophy in patients undergoing anterior cruciate ligament reconstruction (ACLR). Following ACLR, patients will undergo a rehabilitation protocol either w/ BFR therapy or sham BFR therapy.
Read the detailed description
Patients will be randomized to either BFR therapy or no BFR therapy. Randomization will be carried out using block randomization with blocks of 6.
Those undergoing BFR therapy will have a Delfi Personalized Tourniquet System (PTS) cuff applied to the proximal thigh of their operative leg and inflated to 80% limb occlusive pressure (LOP) calculated by the Delfi PTS device during physical therapy (PT) sessions from day 2 after surgery through day 7 after surgery. Those in the no BFR group will have the Delfi PTS cuff applied to their proximal thigh with inflation of the tourniquet to minimal pressure only. BFR therapy will be administered by health care providers who have undergone training and certification for BFR therapy with the Delfi PTS device.
Both groups will undergo the following PT regimen two times daily beginning on the day after the surgical procedure and lasting for 6 weeks post-operatively:
- Quad sets = x1 min isometric hold, 30 sec off, 3 sets
- Terminal knee extensions = 3x15, 30 sec rest or short arc quads sitting 1 x 30 + 3 x 15, 30 sec rest
- Once range of motion (ROM) allows: Bike 10 mins, low to no resistance
Each physical therapy visit will last approximately 60 minutes. During that time, there will be a total estimated time of 5-7 minutes during which the tourniquet cuff will be on the thigh, and the tourniquet will be inflated for a similar time period. The tourniquet will inflate for about 1 minute in order to find out the specific pressure for the patient's leg and then will remain inflated until exercises are completed, which should take 4-6 minutes. The cuff will then be deflated and is removed from the leg within about 30 seconds of being deflated.
Patients will have MRI performed pre-operatively and at 6 weeks post-operatively with axial cuts to 50% femoral length above joint line. Quadriceps cross-sectional area will be measured by a blinded observer using MRI. Patients will have clinical measurements including thigh girth, Lachman test, knee joint range of motion, and knee joint swelling performed pre-operatively, at post-op day 1, post-op day 14, and 6 weeks post-operatively. All clinical measurements will be performed by a blinded observer. Additionally, patient reported pain level will be obtained at the same timepoints in which clinical measurements are performed using visual analog scale.
In order to ensure there are no nerve injuries present in patients prior to undergoing application and inflation of thigh tourniquet, all patients in the study will have single shot adductor and/or sciatic nerve blocks to ensure 24 hour period without nerve block prior to initiation of BFR therapy. Patients included in the study cannot have a nerve block lasting longer than the day of surgery. To ensure no new nerve deficits are present, the patients will undergo a physical examination during morning rounding on post-operative day 1 to assess for new nerve deficits.
- Conditions
- ACL Injury, Quadriceps Muscle Atrophy
- Being tested
- Blood flow restriction therapy - with Delfi Personalized Tourniquet System, Sham blood flow restriction therapy - with Delfi Personalized Tourniquet System
- Medical subject headings
- Anterior Cruciate Ligament Injuries
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Blood flow restriction therapy - with Delfi Personalized Tourniquet SystemDevice
Physical therapy performed with Blood flow restriction therapy tourniquet inflated to 80% limb occlusion pressure
Sham blood flow restriction therapy - with Delfi Personalized Tourniquet SystemDevice
Physical therapy performed with Blood flow restriction therapy tourniquet inflated to only minimal pressure
| Study group | Role | What they receive |
|---|---|---|
| Control | Sham comparator | Patients in this group will have BFR tourniquet applied but inflated to only minimal pressure. Receives: Device: Sham blood flow restriction therapy - with Delfi Personalized Tourniquet System |
| Blood Flow Restriction (BFR) Therapy | Experimental | Patients in this group will have BFR tourniquet applied and inflated to 80% limb occlusion pressure Receives: Device: Blood flow restriction therapy - with Delfi Personalized Tourniquet System |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Quadriceps Cross-Sectional Area
Change in quadriceps cross-sectional area measured on MRI pre-operatively compared to post-operatively
Measured: Pre-op and 6-weeks post-operative
Secondary outcomes (3)
Numeric rating scale pain
Patient reported pain levels using numeric rating scale (NRS) on a scale of 1-10 where 10 represents maximal pain and 1 represents minimal pain
Measured: Days 1, 14, and 6 weeks after surgery
Thigh girth
Measured thigh girth 15cm above knee joint line
Measured: Days 1, 14, and 6 weeks after surgery
Knee joint range of motion
Measure knee range of motion
Measured: Days 1, 14, and 6 weeks after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Jan 2019
- Study start18 Dec 2018
- Primary completion1 Jun 2019
- Study completion1 Jun 2019
Why it stopped: Investigator separated from institution
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ACL InjuryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Double blinded randomized control trial
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Steadman Philippon Research Institute
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03794570
- Sponsor's protocol ID
- 2018-35
- Acronym
- BFR
- Status last verified
- Dec 2019
- First submitted
- 20 Dec 2018
- Last updated
- 4 Dec 2019
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No: No sharing
Study at a glance
From the registry record, last updated by the sponsor on 4 Dec 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Blood Flow Restriction Therapy to Prevent Muscle Atrophy Following Anterior Cruciate Ligament Reconstruction
- ClinicalTrials.gov ID
- NCT03794570
- Acronym / sponsor ID
- BFR / 2018-35
- Conditions
- ACL Injury, Quadriceps Muscle Atrophy
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: Investigator separated from institution
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Steadman Philippon Research InstituteUniversity, hospital or other
- Study start
- 18 Dec 2018 (actual)
- Primary completion
- 1 Jun 2019 (actual)
- Study completion
- 1 Jun 2019 (actual)
- First posted
- 7 Jan 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a prospective, double-blinded, randomized control trial examining the effect of blood flow restriction (BFR) therapy on reducing post-operative quadriceps atrophy in patients undergoing anterior cruciate ligament reconstruction (ACLR). Following ACLR, patients will undergo a rehabilitation protocol either w/ BFR therapy or sham BFR therapy.
Detailed description
Patients will be randomized to either BFR therapy or no BFR therapy. Randomization will be carried out using block randomization with blocks of 6.
Those undergoing BFR therapy will have a Delfi Personalized Tourniquet System (PTS) cuff applied to the proximal thigh of their operative leg and inflated to 80% limb occlusive pressure (LOP) calculated by the Delfi PTS device during physical therapy (PT) sessions from day 2 after surgery through day 7 after surgery. Those in the no BFR group will have the Delfi PTS cuff applied to their proximal thigh with inflation of the tourniquet to minimal pressure only. BFR therapy will be administered by health care providers who have undergone training and certification for BFR therapy with the Delfi PTS device.
Both groups will undergo the following PT regimen two times daily beginning on the day after the surgical procedure and lasting for 6 weeks post-operatively:
- Quad sets = x1 min isometric hold, 30 sec off, 3 sets
- Terminal knee extensions = 3x15, 30 sec rest or short arc quads sitting 1 x 30 + 3 x 15, 30 sec rest
- Once range of motion (ROM) allows: Bike 10 mins, low to no resistance
Each physical therapy visit will last approximately 60 minutes. During that time, there will be a total estimated time of 5-7 minutes during which the tourniquet cuff will be on the thigh, and the tourniquet will be inflated for a similar time period. The tourniquet will inflate for about 1 minute in order to find out the specific pressure for the patient's leg and then will remain inflated until exercises are completed, which should take 4-6 minutes. The cuff will then be deflated and is removed from the leg within about 30 seconds of being deflated.
Patients will have MRI performed pre-operatively and at 6 weeks post-operatively with axial cuts to 50% femoral length above joint line. Quadriceps cross-sectional area will be measured by a blinded observer using MRI. Patients will have clinical measurements including thigh girth, Lachman test, knee joint range of motion, and knee joint swelling performed pre-operatively, at post-op day 1, post-op day 14, and 6 weeks post-operatively. All clinical measurements will be performed by a blinded observer. Additionally, patient reported pain level will be obtained at the same timepoints in which clinical measurements are performed using visual analog scale.
In order to ensure there are no nerve injuries present in patients prior to undergoing application and inflation of thigh tourniquet, all patients in the study will have single shot adductor and/or sciatic nerve blocks to ensure 24 hour period without nerve block prior to initiation of BFR therapy. Patients included in the study cannot have a nerve block lasting longer than the day of surgery. To ensure no new nerve deficits are present, the patients will undergo a physical examination during morning rounding on post-operative day 1 to assess for new nerve deficits.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Double blinded randomized control trial
| Arm | Type | Receives |
|---|---|---|
| Control | Sham comparator | Device: Sham blood flow restriction therapy - with Delfi Personalized Tourniquet SystemPatients in this group will have BFR tourniquet applied but inflated to only minimal pressure. |
| Blood Flow Restriction (BFR) Therapy | Experimental | Device: Blood flow restriction therapy - with Delfi Personalized Tourniquet SystemPatients in this group will have BFR tourniquet applied and inflated to 80% limb occlusion pressure |
Who may qualify
- Ages
- 14 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (5 listed)
- Age 14-70
- Undergoing ACL reconstruction with patellar tendon autograft
- Full weightbearing after surgery
- Surgery performed within 14 days of ACL injury
- No nerve catheter in place
Key exclusion criteria (15 listed)
- Meniscal root tears
- radial meniscal tears
- multi-ligament knee injury
- revision ACL reconstruction
- concomitant osteotomies
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Blood flow restriction therapy - with Delfi Personalized Tourniquet SystemPhysical therapy performed with Blood flow restriction therapy tourniquet inflated to 80% limb occlusion pressure | Device | Blood Flow Restriction (BFR) Therapy |
| Sham blood flow restriction therapy - with Delfi Personalized Tourniquet SystemPhysical therapy performed with Blood flow restriction therapy tourniquet inflated to only minimal pressure | Device | Control |
Primary outcome
Change in Quadriceps Cross-Sectional Area
Time frame: Pre-op and 6-weeks post-operative
Change in quadriceps cross-sectional area measured on MRI pre-operatively compared to post-operatively
3 secondary outcomes
Numeric rating scale pain
Time frame: Days 1, 14, and 6 weeks after surgery
Thigh girth
Time frame: Days 1, 14, and 6 weeks after surgery
Knee joint range of motion
Time frame: Days 1, 14, and 6 weeks after surgery
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Dec 2019.
- Individual participant dataSharing planned: No. No sharing
Related trials for ACL Injury
RecruitingObservational study
BioBrace® Augmentation in Anterior Cruciate Ligament Reconstruction Procedures
ACL Tears
RecruitingPhase 2
Preventing Injured Knees From osteoArthritis: Severity Outcomes
Osteoarthritis, Knee, Post-traumatic Osteoarthritis
Recruiting
Quadriceps Strengthening ACL Reconstruction
ACL Tear
RecruitingObservational study
Intraoperative Energy Expenditure During ACL Reconstruction Surgery
ACL Injury, Meniscal Injuries
Recruiting
Soft-tissue Quadriceps Autograft ACL-reconstruction in the Skeletally-immature vs. Hamstrings
ACL - Anterior Cruciate Ligament Rupture
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Blood flow restriction therapy - with Delfi Personalized Tourniquet System in people with ACL Injury and Quadriceps Muscle Atrophy, run by Steadman Philippon Research Institute at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 4 Dec 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Quadriceps Cross-Sectional Area (time frame: Pre-op and 6-weeks post-operative). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Dec 2019; AzTrials last refreshed its copy on 28 Oct 2026.